Transcatheter Aortic Valve Replacement: OPTIMIZING OUTCOMES FOR HEALTHY RECOVERY

Area of Science:

• Cardiology
• Interventional Cardiology
• Medical Devices

Background:

• Transcatheter aortic valve replacement (TAVR) is approved for intermediate and high-risk patients with severe symptomatic aortic stenosis in the US.
• Over 80,000 TAVR procedures have been performed, with increasing annual numbers.
• Approved valve designs include balloon-expandable (Edwards Sapien) and self-expanding (CoreValve) prostheses.

Purpose of the Study:

• To review the efficacy and safety of TAVR for severe symptomatic aortic stenosis.
• To discuss major complications, valve durability concerns, and the role of cardiac rehabilitation in post-TAVR patients.

Main Methods:

• Review of data from the PARTNER trial and other randomized controlled trials comparing TAVR with surgical aortic valve replacement.
• Analysis of complication rates, including stroke, pacemaker implantation, and vascular complications.
• Evaluation of 5-year follow-up data and the impact of cardiac rehabilitation on patient outcomes.

Main Results:

• The PARTNER trial showed a 19% absolute risk reduction in mortality for inoperable patients treated with TAVR compared to medical therapy.
• Randomized trials demonstrated TAVR non-inferiority to surgical aortic valve replacement in high and intermediate-risk patients.
• Major complications include a 2-3% stroke risk, 8-25% pacemaker implantation rate, and 6% major vascular complications.
• Five-year follow-up indicates appropriate valve performance, but longer data is needed for structural deterioration assessment.
• Cardiac rehabilitation is safe and improves exercise capacity, functional independence, and frailty in post-TAVR patients.

Conclusions:

• TAVR is a viable treatment for severe symptomatic aortic stenosis in intermediate and high-risk patients.
• While generally safe, TAVR carries risks of stroke, pacemaker implantation, and vascular complications.
• Long-term valve durability requires further investigation, especially for younger, lower-risk patients.
• Cardiac rehabilitation is crucial for optimizing recovery and functional outcomes in TAVR patients, particularly the frail.